-
Cipher Pharmaceuticals Inc. (CPH $12.72)
- $12.72 P/E (TTM): 25.05X Cap: $325M
- View CPH Profile
- View Questions on CPH
- View Reports on CPH
Detailed Quote
5i Report
Review of Cipher Pharmaceuticals
AUG 16, 2018 - Dermatology pharmaceutical business with recent acquisition and growth in product pipeline, with some mixed results in the past. Coverage dropped until some visibility emerges.
Download ReportCompany Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
Cipher Pharmaceuticals Inc. (CPH $12.72)
- $12.72 P/E (TTM): 25.05X Cap: $325M
- View CPH Profile
- View Questions on CPH
- View Reports on CPH
Q: There hasn't been an update on this company for some time. Can you provide EPS and Revenue growth forecasts going forward. It has trended down since mid last year and wondering if more patience is warranted. Thank you.
-
Cipher Pharmaceuticals Inc. (CPH $12.72)
- $12.72 P/E (TTM): 25.05X Cap: $325M
- View CPH Profile
- View Questions on CPH
- View Reports on CPH
Q: Please comment on CPH latest earnings. It looks like a bit of a mixed bag. The stock is expensive, but they are throwing off a lot of FCF and their strategy looks solid going forward. Thank you.
-
Cipher Pharmaceuticals Inc. (CPH $12.72)
- $12.72 P/E (TTM): 25.05X Cap: $325M
- View CPH Profile
- View Questions on CPH
- View Reports on CPH
Q: A bit of an earnings miss, but the future is looking promising. Your opinion going forward please.
Insiders
Share Information
News and Media